Michael David Jain

This study shows that durable CAR-T therapy in lymphoma requires cooperation with endogenous CD8 T cells, and tumors lacking MHC class I or CD58 resist treatment.

This study links low stool valerate to CAR T-cell dysfunction in B-cell lymphoma and shows valerate supplementation improves CAR T function.

This study identifies a Th1/Th17 imbalance driven by IFN{gamma} that causes cytokine release syndrome and neutropenia in CAR-T therapy, suggesting IFN{gamma} blockade as a potential treatment.

The paper investigates the mutagenic impact of radiotherapy in hematologic malignancies and finds that RT contributes to the ID8 mutational signature, which is associated with treatment resistance and relapse.

This study finds that clonal hematopoiesis mutations, particularly in DNMT3A, TET2, and ASXL1, are linked to increased toxicity in patients undergoing anti-CD19 CAR T-cell therapy for large B-cell lymphoma.